Ionis Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.03.23	New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease (PR Newswire)
28.03.23	Ionis to present at upcoming investor conferences (PR Newswire)
27.03.23	Ionis Pharma Reports Positive 66-week Results Of Eplontersen Phase 3 Study In ATTRv-PN (RTTNews)
27.03.23	Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN (PR Newswire)
23.03.23	Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS (PR Newswire)
07.03.23	Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) (PR Newswire)
28.02.23	Ionis to present at upcoming investor conferences (PR Newswire)
22.02.23	Ionis reports fourth quarter and full year 2022 financial results (PR Newswire)
21.02.23	Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting (PR Newswire)
08.02.23	Ionis to hold fourth quarter and full year 2022 financial results webcast (PR Newswire)
01.02.23	Ionis announces GSK has advanced bepirovirsen into Phase 3 development (PR Newswire)
31.01.23	Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome (PR Newswire)
26.01.23	Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research (PR Newswire)
09.01.23	Royalty Pharma Acquires Ionis' Royalty In Spinraza, Pelacarsen For $1.125 Bln (RTTNews)
09.01.23	Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness (PR Newswire)
04.01.23	Ionis to present at 41st Annual J.P. Morgan Healthcare conference (PR Newswire)
05.12.22	Ionis Announces EMA's Acceptance Of Marketing Authorization Application Of Tofersen For SOD1-ALS (RTTNews)
05.12.22	Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS (PR Newswire)
14.11.22	Ionis partners with Metagenomi to add gene editing to its broad technology platform (PR Newswire)
13.11.22	Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting (PR Newswire)
10.11.22	Ionis to present at upcoming investor conferences (PR Newswire)
09.11.22	Ionis reports third quarter financial results (PR Newswire)
08.11.22	Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen (PR Newswire)
07.11.22	Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022 (PR Newswire)
04.11.22	Ionis announces positive results from fesomersen development program (PR Newswire)
26.10.22	Ionis to hold third quarter 2022 financial results webcast (PR Newswire)
23.09.22	Ionis: AstraZeneca Decides Not To Advance ION449 Into Phase 3 Based On Pre-specified Criteria (RTTNews)
23.09.22	Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia (PR Newswire)
07.09.22	Ionis Presents Positive Results From Phase 3 Study Of Eplontersen In Neuropathy Impairment (RTTNews)
07.09.22	Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis (PR Newswire)
30.08.22	Ionis to present at upcoming investor conferences (PR Newswire)
09.08.22	Ionis reports second quarter financial results and recent business achievements (PR Newswire)
28.07.22	Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment (PR Newswire)
27.07.22	Ionis to hold second quarter 2022 financial results webcast (PR Newswire)
26.07.22	Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS (PR Newswire)
20.07.22	Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen (PR Newswire)
13.07.22	Ionis to participate in virtual fireside chat at H.C. Wainwright 1st Annual Hereditary Angioedema Conference (PR Newswire)
11.07.22	Ionis Says Partner Roche Licenses And Advances Rare Kidney Disease Treatment Into Phase 3 Trial (RTTNews)
11.07.22	Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study (PR Newswire)
26.06.22	Ionis : GSK Presents Positive Phase 2b Data For Chronic Hepatitis B Treatment (RTTNews)
25.06.22	Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™ (PR Newswire)
21.06.22	AstraZeneca Posts Positive Interim Data In Eplontersen Phase III Trial In ATTRv-PN - Quick Facts (RTTNews)
21.06.22	Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) (PR Newswire)
13.06.22	Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA (PR Newswire)
03.06.22	Ionis: Tofersen Slows Disease Progression In Phase 3 VALOR Study (RTTNews)
03.06.22	Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients (PR Newswire)
12.05.22	Ionis to present at RBC Capital Markets Global Healthcare Conference (PR Newswire)
04.05.22	Ionis reports first quarter financial results and recent business achievements (PR Newswire)
02.05.22	Ionis to host 2022 virtual Annual Meeting of Stockholders (PR Newswire)
20.04.22	Ionis to hold first quarter 2022 financial results webcast (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

25.11.24		Freundlicher Handel: NASDAQ Composite-Börsianer greifen zum Handelsstart zu
15.11.24		Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge
10.09.24		Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels auf grünem Terrain
10.09.24		Pluszeichen in New York: Anleger lassen NASDAQ Composite am Nachmittag steigen
10.09.24		Schwacher Handel: So entwickelt sich der NASDAQ Composite aktuell
10.09.24		Freundlicher Handel: NASDAQ Composite startet im Plus
30.08.24		Börse New York in Grün: NASDAQ Composite beendet die Sitzung im Plus
27.08.24		Optimismus in New York: NASDAQ Composite liegt schlussendlich im Plus

25.11.24

Freundlicher Handel: NASDAQ Composite-Börsianer greifen zum Handelsstart zu

15.11.24

Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge

10.09.24

Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels auf grünem Terrain

10.09.24

Pluszeichen in New York: Anleger lassen NASDAQ Composite am Nachmittag steigen

10.09.24

Schwacher Handel: So entwickelt sich der NASDAQ Composite aktuell

10.09.24

Freundlicher Handel: NASDAQ Composite startet im Plus

30.08.24

Börse New York in Grün: NASDAQ Composite beendet die Sitzung im Plus

27.08.24

Optimismus in New York: NASDAQ Composite liegt schlussendlich im Plus

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Ionis Pharmaceuticals Inc

Aktien Top/Flop

Ionis Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten